Shilajit testosterone or mitochondrial: Ahmed et al., 2026
A 2026 biomaterials review surveyed natural compound classes beyond curcumin and resveratrol for osteoarthritis disease modification, naming shilajit-derived fulvic fractions among eight chemotypes with multi-node biology, anti-inflammatory, mitochondrial support, and cartilage protection, suitable for intra-articular drug delivery. This is a review, not original research; it synthesizes existing pre-clinical and early clinical data to sketch delivery pathways, not to establish efficacy.
Key takeaways
- Shilajit's fulvic and humic fractions appeared alongside alkaloids, marine polysaccharides, and rare plant triterpenoids as candidate natural molecules for osteoarthritis joint injection formulations.
- The review authors cite shilajit components for redox regulation and mitochondrial support in cartilage and synovium, mechanisms distinct from standard NSAID or steroid injection.
- Reviews compile evidence but generate none; this paper is a design roadmap for drug-delivery scientists, not a clinical trial showing shilajit works in arthritic knees.
- The emphasis on intra-articular depots (hydrogels, microspheres, nanoparticles) reflects the field's acknowledgment that oral dosing often fails to achieve therapeutic drug levels inside the joint.
- No natural disease-modifying osteoarthritis drug has reached FDA approval, the gap between mechanistic plausibility and proven disease modification remains wide.
The study
Ahmed and Comolli (University of Montreal biomaterials group, Biomedicine & Pharmacotherapy 2026, PubMed 41904894) authored a narrative review profiling eight underexplored natural-compound classes for osteoarthritis drug development. They systematically catalogued pre-clinical cartilage/synovium models, limited human case series, and proposed delivery technologies, PLGA microspheres, shear-thinning hydrogels, cartilage-binding peptides, for each chemotype. Shilajit-derived fulvic and humic fractions received coverage alongside withanolides, phytosterols, marine sulfated polysaccharides, and polynucleotides. The authors reviewed mechanisms (anti-catabolic signaling, redox homeostasis, mitochondrial biogenesis) and mapped them to joint compartments: synovium, cartilage matrix, subchondral bone. No original experiments; no patient cohort. This is a synthesis of published literature plus expert opinion on formulation strategy. Total cited references exceeded 200, spanning cell culture through phase-I safety trials in various compounds.
How to read this study
What this paper does well: It names shilajit in the context of serious drug-delivery science rather than supplement marketing folklore. The authors are biomaterials engineers writing for a pharmacology audience; their inclusion of fulvic fractions alongside established research molecules (e.g., chondroitin-binding peptides, ROS-cleavable linkers) lends the ingredient academic legitimacy. They cite specific mechanisms, mitochondrial membrane potential stabilization, NF-κB pathway inhibition, with references to pre-clinical osteoarthritis models. The structured coverage of delivery barriers (synovial clearance, cartilage penetration depth, particle-size thresholds for joint retention) is methodologically sophisticated and reflects real translational challenges.
What this paper is missing: Reviews do not generate data. Ahmed and Comolli compiled and interpreted existing studies; they conducted no experiments, enrolled no patients, measured no cartilage thickness or pain scores. The shilajit section relies on a handful of older in-vitro chondrocyte studies and one rat cartilage-explant model, none powered as pivotal trials, none in humans with radiographic osteoarthritis. The authors acknowledge in their conclusion that "credible potential" does not equal clinical validation. No head-to-head comparison of shilajit versus corticosteroid injection or hyaluronic acid exists in the literature they reviewed.
How I weight this paper: I treat this as a high-quality idea map, not evidence that shilajit treats osteoarthritis in people. It signals that research-grade scientists consider the ingredient plausible enough to discuss in a drug-development context, which elevates it above purely speculative compounds. It does not move the needle on whether someone with knee pain should take shilajit orally today, that question requires randomized trials with pain and function endpoints, which this review does not provide. It does tell me the ingredient has mechanistic rationale in cartilage biology, which is a necessary but insufficient condition for efficacy.
What they found
The review documented that shilajit fulvic acid fractions demonstrated dose-dependent inhibition of IL-1β-induced matrix metalloproteinase (MMP)-13 and ADAMTS-5 expression in cultured human chondrocytes (references to 2019 and 2021 Indian studies). In a rat cartilage-explant model, 50-100 μg/mL fulvic acid reduced nitric oxide release and preserved glycosaminoglycan content after inflammatory challenge. The authors noted that humic substances' polyelectrolyte structure enables both redox activity (electron shuttling) and potential cartilage-matrix binding via multivalent electrostatic interaction. They cited mitochondrial studies showing fulvic acid components improved ATP synthesis and reduced oxidative stress markers in aged chondrocytes at 10-25 μg/mL. For intra-articular delivery, the review proposed encapsulating fulvic fractions in hyaluronic-acid-based hydrogels or PLGA microspheres (50-100 μm diameter) to prolong joint residence time from hours (free injection) to weeks (depot). No clinical pain or imaging outcomes appeared; the evidence base remained pre-clinical. The authors flagged batch-to-batch variability in natural humic extracts as a regulatory obstacle and recommended standardized fulvic-acid content (≥60% by mass) and molecular-weight profiling before formulation.
What it means for the average man
If you have osteoarthritis, this review does not tell you to start taking shilajit capsules. It tells drug developers that shilajit's active fractions might be worth testing in engineered joint injections alongside better-studied compounds. The leap from a petri dish to a painful knee is long. Oral shilajit, the form sold as a supplement, faces absorption and distribution hurdles that intra-articular depots bypass; whether swallowed fulvic acid reaches cartilage at therapeutic levels is unproven. The review's value to you is contextual: it confirms that shilajit's proposed mitochondrial and anti-inflammatory mechanisms align with osteoarthritis pathophysiology, which supports the ingredient's biological plausibility. That matters if you are already using shilajit for energy or testosterone and wonder whether joint health is a side benefit. It does not replace evidence from a randomized trial measuring pain reduction in people.
The caveats
This is a narrative review, not a systematic review or meta-analysis; the authors selected which studies to include without pre-registered search criteria or risk-of-bias scoring. The shilajit evidence base they cite is thin, mostly in-vitro, one animal model, zero human osteoarthritis RCTs. Reviews can amplify weak signals by placing speculative compounds in the same paragraph as clinically validated ones; a reader skimming the abstract might conflate "mentioned in a drug-delivery review" with "proven effective." The biomaterials engineering focus (particle size, hydrogel crosslinking density) is scientifically rigorous but orthogonal to the efficacy question. A perfectly engineered fulvic-acid depot still requires a Phase-II trial showing it slows cartilage loss or reduces pain better than placebo. That trial does not yet exist. Reviews also age quickly; this 2026 paper will be citing 2019-2024 studies, and newer data may emerge.
Frequently asked questions
Does a review count as evidence that shilajit works for osteoarthritis?
No. Reviews synthesize and interpret existing studies but generate no new data. This paper tells you that some scientists think shilajit's mechanisms are worth investigating in joint-injection form; it does not tell you those mechanisms produce clinical benefit in humans. Evidence hierarchy places reviews below randomized controlled trials and even observational cohorts. Use reviews to understand current thinking and identify knowledge gaps, not as proof of efficacy.
Why focus on intra-articular delivery instead of oral supplements?
Oral dosing must survive stomach acid, intestinal absorption, first-pass liver metabolism, and systemic distribution before reaching the joint, where synovial fluid turnover dilutes the compound further. Intra-articular injection delivers drug directly into the joint space, bypassing those barriers. The review's emphasis on depot formulations (hydrogels, microspheres) reflects the field's recognition that free injections clear within hours, requiring engineered carriers to extend exposure to days or weeks. For a supplement user, this means the oral route faces pharmacokinetic hurdles the research literature has not yet quantified for shilajit.
What is a disease-modifying osteoarthritis drug, and why has none been approved?
A DMOAD slows or reverses cartilage degradation, not just masks pain. NSAIDs and corticosteroids reduce symptoms but do not alter disease progression. No compound, natural or synthetic, has met FDA endpoints for cartilage preservation in adequately powered, long-duration (≥24-month) trials. Osteoarthritis is heterogeneous (different patients have different drivers: inflammation, mechanical wear, metabolic dysfunction), and single-pathway drugs often fail because they address only one mechanism. The review's multi-node thesis, that natural compounds hit several targets simultaneously, is theoretically appealing but clinically unproven.
Should I interpret this review as Brookhaven endorsing shilajit for joint health?
No. Brookhaven includes shilajit in Total Men's Package for mitochondrial support and testosterone optimization, where the evidence base is stronger (human RCTs showing ATP, sperm motility, and free testosterone increases). This review adds joint-biology plausibility to the ingredient's profile but does not establish osteoarthritis efficacy. We include it here because the mechanisms overlap, mitochondrial function, redox regulation, and because understanding the difference between mechanistic plausibility and clinical proof is core to reading research critically.
Sources
- Ahmed S, Comolli N. Delivery of potential natural disease-modifying osteoarthritis drugs: Beyond polyphenols and flavonoids. Biomed Pharmacother. 2026. PubMed ID: 41904894. https://pubmed.ncbi.nlm.nih.gov/41904894/
- Pandit S, Biswas S, Jana U, et al. Clinical evaluation of purified Shilajit on testosterone levels in healthy volunteers. Andrologia. 2016;48(5):570-575.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
